SPI Infoamtion

Table of Contents

Executive summary

Background
Stem cell research and development: scope and status
Commercial landscape
Industry landscape

Chapter 1 Background

Summary
Introduction

The building blocks of life

About stem cells

Potency
Stem cell division
Stem cell research

Human ESCs

Current status of knowledge

Embryonic stem cells

Growth and identification of ESCs
Stimulating ESCs to differentiate

Adult stem cells
Cord blood stem cells
Induced pluripotent stem cells
Nuclear reprogramming
Ethical and regulatory issues

Situation in the US
European regulations

Chapter 2 Stem cell research and development: scope and status

Summary
Introduction
Practical applications of stem cells

Disease treatment

Amyotrophic lateral sclerosis
Parkinson's disease
Spinal cord injury
Alzheimer's disease
Cancer
Heart disease
Peripheral arterial disease
Type 1 diabetes
Liver failure
Graft-versus-host disease

Stem cell models: applications in drug discovery

Screening studies
Toxicity studies
Practical benefits
Some skepticism remains

Chapter 3 Commercial landscape

Summary
Resisting the hyperbole
Market realities

Cell-based therapy market

Autologous SC therapy
Allogeneic SC therapy

Cord blood banks
Market drivers
Market

Global market estimates and forecasts

Global market by use
Global market by country share

Embryo vs. adult stem cells
Investment opportunities

Choosing a viable business model

Matching the model to the circumstance
Autologous therapy models
Allogeneic therapy models

Chapter 4 Industry landscape

Summary
Introduction
Company profiles

Aastrom Biosciences, Inc.

Overview
Pipeline

Advanced Cell Technology, Inc.

Overview
Pipeline
Collaboration

Aldagen

Overview
Pipeline
Collaboration

Angioblast Systems, Inc.

Overview
Pipeline

Athersys, Inc.

Overview
Pipeline
Collaboration
Financials

Bioheart, Inc.

Overview
Pipeline

Bionet

Overview
Collaboration

Brainstorm Cell Therapeutics

Overview

Capricor, Inc.

Overview
Pipeline
Collaboration

Cardio3 BioSciences SA

Overview

Cellcyte Genetics

Overview
Pipeline
Collaboration

Cellerix SA

Overview
Pipeline

CellGenix Technologie Transfer

Overview

Cytori Therapeutics, Inc.

Overview

Entest BioMedical, Inc.

Overview

ES Cell International

Overview

EvoStem Finland Oy

Overview

Fate Therapeutics, Inc.

Overview

Genzyme

Collaboration
Financials

Geron

Overview
Pipeline

Healtheuniverse, Inc.

Overview

Innovacell Biotechnologie AG

Overview

International Stem Cell Corporation (ISCO)

Overview
Financing

iPierian, Inc.

Overview

Ixion Biotechnology, Inc.

Overview

Karocell Tissue Engineering AB

Overview

MedCell Bioscience Ltd

Overview

MediStem, Inc.

Overview
Pipeline

Mesoblast Limited

Overview

Nephrogenix

Overview

Neuralstem, Inc.

Overview
Pipeline
Collaboration

OncoStem Pharma

Overview

Novocell, Inc.

Overview

NuVasive, Inc.

Overview

Osiris Therapeutics, Inc.

Overview
Pipeline
Collaboration
Financials

Pharmicell Europe GmbH

Overview

PrimeGen Biotech

Overview

Opexa Therapeutics

Overview
Financing
Financials

Plureon

Overview
Pipeline
Collaboration

Proteonomix, Inc.

Overview

Regenerative Sciences, Inc.

Overview

ReNeuron

Overview
Pipeline

Shenzhen Beike

Overview

Stematix, Inc.

Overview

StemCells, Inc.

Overview

Stem Cell Therapeutics

Overview

Stem Cell Therapy International

Overview

Stemedica Cell Technologies, Inc.

Overview

Stempeutics Research Pvt. Ltd.

Overview

t2cure GmbH

Overview

TICEBA GmbH

Overview

Tristem

Overview

Chapter 5 Appendix

Methodology
Glossary
Index

List of Figures
Figure 1.1: Early embryonic development and later differentiation
Figure 1.2: Stem cell division
Figure 1.3: Induced pluripotent stem cells
Figure 2.4: Stem cell opportunities in disease treatment and R&D
Figure 3.5: Forces affecting the stem cell market
Figure 3.6: Key challenges faced when developing autologous therapy
Figure 4.7: Type and number of regenerative medicine organizations

List of Tables
Table 3.1: Global stem cell market ($m), 2008-14
Table 3.2: Potential US patient populations for cell-based therapies
Table 3.3: Stem cell market by main uses ($m), 2008-14
Table 3.4: Country breakdown of stem cell market ($m), 2008-14
Table 3.5: Leading cell-based regenerative medicine products